HLS Therapeutics Inc. (TSX:HLS)
4.210
+0.010 (0.24%)
Jul 22, 2026, 3:59 PM EST
HLS Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, HLS Therapeutics stock has a consensus rating of "Buy" and an average price target of $7.28. The average 1-year stock price forecast is 72.92% higher than the current stock price, while the lowest is $4.59 (+9.03%) and the highest is $12.27 (+191.45%).
Price Target: $7.28 (+72.92%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on May 19, 2026.
Analyst Ratings
The average analyst rating for HLS Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Nov '25 | Dec '25 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 2 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Initiates $5.00 | Hold | Initiates | $5.00 | +18.76% | May 19, 2026 |
| Bloom Burton | Bloom Burton | Buy Maintains $12.00 | Buy | Maintains | $12.00 | +185.04% | May 19, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $4.75 → $4.45 | Hold | Maintains | $4.75 → $4.45 | +5.70% | Mar 12, 2026 |
Financial Forecast
Revenue This Year
58.03M
from 55.50M
Increased by 4.56%
Revenue Next Year
64.31M
from 58.03M
Increased by 10.83%
EPS This Year
-0.20
from -0.39
EPS Next Year
-0.03
from -0.20
EPS and Forward PE are based on non-GAAP adjusted numbers.